Back
Open Access

Expert panel: What are the implications for our practice?

Session: When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
Topic: Treatment
Speaker: Professor J. McMurray (Glasgow, GB) Professor C. Lam (Singapore, SG) Professor S. Solomon (Boston, US)
Sponsored by PACE-CME – Supported by an unrestricted educational grant from AstraZeneca
Event: Heart Failure 2022

Congress Presentation

About the speakers

Professor John J V McMurray

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
125 presentations
16 followers

Professor Carolyn Sp Lam

Duke-NUS Graduate Medical School Singapore, Singapore (Singapore)
147 presentations
50 followers

Professor Scott Solomon

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
65 presentations
22 followers

3 more presentations in this session

The clinical challenges of initiating guideline-recommended therapy in HFrEF.

Speaker: Professor J. McMurray (Glasgow, GB)

Access
Slides
Video
Thumbnail

Benefits and evolving insights on SGLT2i in the spectrum of LVEF: can we set priorities?

Speaker: Professor C. Lam (Singapore, SG)

Access
Slides
Video
Thumbnail

Expanding evidence on SGLT2i: where are we now and what can we expect?

Speaker: Professor S. Solomon (Boston, US)

Access
Slides
Video
Thumbnail

Access the full session

When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

Speakers: Professor J. McMurray, Professor C. Lam, Professor S. Solomon, Professor J. McMurray, Professor C. Lam...
Access
Video
Thumbnail

About the event

Image

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb